A Phase II Trial of Pemetrexed Versus Erlotinib as Second-Line Therapy in Treating Patients With EGFR Wild-type Advanced Lung Adenocarcinoma
This trial will compare the efficacy of pemetrexed versus erlotinib in patients with EGFR
wild-type advanced lung adenocarcinoma.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
1 year
No
Siyu Wang, Doctor
Principal Investigator
Sun Yat-sen University
China: Ethics Committee
wsy001
NCT01565538
April 2012
Name | Location |
---|